By Cristina Gallardo
The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.
The Food and Drug Administration's announcement confirms that the U.S. supply of these prescription-only drugs now meets or exceeds the current and projected demand in the country, the pharmaceutical company said Friday.
Novo Nordisk added that it continues to produce Wegovy and Ozempic around the clock, seven days a week, in order to meet the sky-rocketing demand.
"No one should have to compromise their health due to misinformation and reach for fake or illegitimate knock-off drugs that pose significant safety risks to patients," said Dave Moore, executive vice president for U.S. Operations at Novo Nordisk.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
February 21, 2025 10:30 ET (15:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。